Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Portal hypertension is a lethal complication of cirrhosis. Its mechanism and therapeutic targets remain largely unknown. Hepatic stellate cell (HSC) contraction increases intrahepatic vascular resistance contributing to portal hypertension. We investigated how HSC contraction was regulated by Wnt signaling and the therapeutic implication.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Liver tissues from cirrhotic patients were examined. Cirrhotic mice with genetic or pharmacological treatments were used for <i>in vivo</i> assessments and their primary cells were isolated. Cellular functions and signaling pathways were analyzed in human HSC‐LX2 cells using real‐time PCR, Western blotting, siRNA, luciferase reporter assay, chromatin immunoprecipitation, co‐immunoprecipitation, and site‐directed mutagenesis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Wnt/β‐catenin correlated with HSC contraction in human cirrhotic liver. Wnt3a stimulated Smo‐independent Gli1 nuclear translocation followed by LARG‐mediated RhoA activation leading to HSC contraction. Sufu negatively mediated Wnt3a‐induced Gli1 nuclear translocation. Wnt/β‐catenin repressed the transcription of Sufu dependent on β‐catenin/TCF4 interaction and TCF4 binding to Sufu promoter. Molecular simulation and site‐directed mutagenesis identified the β‐catenin residues Lys312 and Lys435 critically involved in the interaction. Additionally, TCF4 binding to the sequence CACACCTTCC at Sufu promoter was required for transrepression of Sufu. In cirrhotic mice, short‐term liver‐targeting β‐catenin deficiency or acute treatment with β‐catenin inhibitors reduced portal pressure via restriction of HSC contraction rather than inhibition of HSC activation. Long‐term deficiency or treatments also ameliorated liver injury, fibrosis and inflammation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>Interaction between Wnt/β‐catenin and Smo‐independent Gli1 pathways promoted HSC contraction via TCF4‐dependent transrepression of Sufu. HSC‐specific inhibition of β‐catenin may have therapeutic benefits for cirrhotic portal hypertension.</p></section>

Intrahepatic upregulation of MRTF-A signaling contributes to increased hepatic vascular resistance in cirrhotic rats with portal hypertension.

Circular RNA Circube2k Promotes Hepatic Fibrosis Via Sponging Mir‐149‐5p/tgf‐β2 Axis

C1q/tumor Necrosis Factor-Related Protein-3 Acts As a Target Treating Hepatic Fibrosis

Bacterial Translocation Aggravates CCl4-induced Liver Cirrhosis by Regulating CD4+ T Cells in Rats

Intestinal Microbiota and Innate Immunity-Related Gene Alteration in Cirrhotic Rats with Liver Transplantation

The Increase of Long Noncoding RNA Fendrr in Hepatocytes Contributes to Liver Fibrosis by Promoting IL-6 Production

SRF/MRTF-A and liver cirrhosis: Pathologic associations

The MSP‐RON Pathway Regulates Liver Fibrosis Through Transforming Growth Factor Beta‐dependent Epithelial–mesenchymal Transition

Liver function improvement following increased portal blood flow in cirrhotic rats

Research progress on signaling pathways in cirrhotic portal hypertension

Inhibition of soluble epoxide hydrolase reduces portal pressure by protecting mesenteric artery myogenic responses in cirrhotic rats.

Activation of the Mir-34A/sirt1/p53 Signaling Pathway Contributes to the Progress of Liver Fibrosis Via Inducing Apoptosis in Hepatocytes but Not in HSCs.

Imperatorin attenuates CCl4-induced cirrhosis and portal hypertension by improving vascular remodeling and profibrogenic pathways

Resveratrol Alleviates Hepatic Fibrosis in Associated with Decreased Endoplasmic Reticulum Stress-Mediated Apoptosis and Inflammation

Vitamin D receptor attenuates carbon tetrachloride-induced liver fibrosis via downregulation of YAP

Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1

Telmisartan relieves liver fibrosis and portal hypertension by improving vascular remodeling and sinusoidal dysfunction

The Regulatory Role of AT1 Receptor on Activated HSCs in Hepatic Fibrogenesis: Effects of RAS Inhibitors on Hepatic Fibrosis Induced by CCl4

Integration of high‑throughput data of microRNA and mRNA expression profiles reveals novel insights into the mechanism of liver fibrosis.

Decreased Portal Circulation Augments Fibrosis and Ductular Reaction in Nonalcoholic Fatty Liver Disease in Mice

MicroRNA-130a and -130B Enhance Activation of Hepatic Stellate Cells by Suppressing PPARγ Expression: A Rat Fibrosis Model Study.